F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

The New York Times – Business:

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

Gina Kolata and Rebecca Robbins
Author: Gina Kolata and Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Gina Kolata and Rebecca Robbins

in

, , , , ,

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

More posts